C&L: Ivrea taps Daniel Lynch for top job

Ivrea Pharmaceuticals has named Daniel S. Lynch as president and CEO. Lynch spent nearly five years at ImClone Systems as both CFO and CEO.

AM-Pharma has named Bart Wuurman, M. Sc. as CEO, replacing Bruno Giannetti, MD., Ph.D., who left AM-Pharma in December.

Christopher J. Moreau has been appointed president and CEO of Miraculins.

Xceed Molecular has promoted David Deems to president.

Renee Reijo-Pera is joining Stanford as head of the Center for Human Embryonic Stem Cell Research and Education within the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

Catalyst Biosciences has appointed Erik Wiberg as the company's CFO.

Targanta Therapeutics has named George Eldridge as the company's new CFO.

Joerg Petrass has been named CFO of Mologen.

Cary Grossman has resigned from his part-time job as CFO of Gentium.

ThromboGenics NV has appointed Patrik De Haes, MD, as COO and Franky Terras as patent counsel.

Marcea Bland Lloyd has been appointed senior vice president, legal and corporate affairs, and general counsel of Amylin Pharmaceuticals.

Acusphere has hired Dennis Bucceri as senior vice president of regulatory affairs.

David D. Waters, MD has joined Anthera Pharmaceuticals as Cardiovascular Research Fellow.

Advitech has appointed François Courteau, CA, as vice-president and COO.

Tikvah Therapeutics has named Sandy Weinberg, Ph.D., as vice president of regulatory affairs and quality assurance.

Xencor has named Jade R. Brown vice president of business development.

Yoshimaru Yamamoto has joined Bioenvision JapanCo as a director and general manager.

Medivir has appointed Börje Darpö as vice president, pharmaceutical development.

Eugene Myers, Ph.D. of the Janelia Farm Research Campus of the Howard Hughes Medical Institute in Ashburn, Virginia, has been added to Helicos BioSciences' scientific advisory board.

Ian F. Smith, executive vice president and chief financial officer of Vertex Pharmaceuticals, has been elected to Acorda Therapeutics' board of directors.

Mark J. Baric has been named to the NovaDel board of directors.

Jonathan Mow has joined AerovectRx's board of directors.

J. Michael Millis, M.D., has been appointed to Vital Therapies' board of directors.

Boston Life Sciences has named Dr. Henry Brem and Gary Frashier as new members of the board of directors.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.